AKT1 and acute myeloid leukemia: Expression of the T-cell surface co-stimulatory molecule, CD28, is involved in the activation of the PI3K/AKT pathway by enhancing the signaling of the T-cell receptor, which affects chemoresistance in AML (Parry et al., 2005).